Neurovative Diagnostics Competitors

Psychemedics develops and delivers the world’s leading hair drug test for detecting drugs of abuse. Some of the most well-known companies in the Fortune 500, largest police departments, and schools across the country use Psychemedics’ patented drug tests using hair to ensure safer workplaces and campuses. After 30 years, the company remains the drug testing industry’s leading innovator and consistently advances the science of hair testing for drugs of abuse. Employing the leading scientists in the field of drug detection science, Psychemedics protects businesses by identifying more drug users for more companies than any other hair testing laboratory in the world. Unique among laboratories, all Psychemedics drug screens are FDA 510k approved. Those tests include the 5 panel drug test and additional tests for emerging threats like fentanyl and benzodiazepines. For more information, visit the Psychemedics website at www.psychemedics.com For more information, visit the Psychemedics website at www.psychemedics.com

Genomind is a leading precision health company focused on optimizing the treatment experience for individuals and healthcare providers through actionable genetic insights and innovative health technology. Since its founding, Genomind has expanded beyond its flagship of pharmacogenetic testing to develop a comprehensive portfolio of precision health services for individual and population-level patient care. Built on the foundation of compassionate care and clinical expertise, Genomind is empowering a more targeted and personalized approach to medication management, and a new standard of care. Genomind's Pharmacogenetic Test is an industry-leading prescription genetic test that equips healthcare professionals with tools they need to more quickly identify a personalized treatment plan for their patients. Genomind offers more comprehensive genetic guidance, superior speed and accuracy, state-of-the-art digital tools, and scheduled PhD and PharmD expert consultations. This test is available via clinician order only. Genomind® Mental Health Map™ is the first-ever genetic test available direct-to-consumer designed specifically for mental health and wellness. It provides powerful new insights and actions through reports in the 7 Core Genetic Mental Health Capabilities™ by analyzing genetic makeup across 35 genes, 38 genetic variants, 21 genetic mechanisms, and 59 mental health predispositions. Included is a free consult to help individuals better take advantage of their results. This test does not inform on medications nor require clinician order. If you are a patient who is interested in our testing, or a clinician interested in using these tools in your practice, please contact us at 877-895-8658 or customerservice@genomind.com. Learn more at www.genomind.com.

BrainScope is a leading neurotechnology company advancing brain health through objective, AI-powered insights derived from brain electrical activity (EEG). Its proprietary platform analyzes EEG data from any source using advanced machine and deep learning to deliver rapid, radiation-free, accessible and cost-effective biomarkers - greatly expanding the clinical utility of traditional EEG. BrainScope's device for head injury assessment was the first device in neurology cleared by the FDA under the AI/Machine Learning-Enabled Medical Device category. BrainScope has commercialized its first set of FDA-cleared biomarkers for mild brain injury assessment (both brain bleeds and concussions) with remarkable outcomes in major U.S. health systems, which include ~50% reduction in unnecessary head CTs, substantial reductions in patient length of stay in emergency departments, and high utility for concussion clinics, personal injury cases and sports. The company is now advancing novel biomarkers for early Alzheimer’s detection, ARIA assessment, rapid stroke evaluation, concussion subtyping, military blast exposure, and others.